Skip to main content

erythromycin lactobionate

Generic: ERYTHROMYCIN LACTOBIONATE·Brand: ERYTHROCIN, ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE

erythromycin lactobionate: sourced relationships with 1 company · 1 FDA decision.

erythromycin lactobionate evidence translation

What we can confirm

What it means

Source-backed records connect erythromycin lactobionate to NEXS; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could erythromycin lactobionate → NEXS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (2)
CompanyDated record stage
NEXUS BIOPHARMA INC (NEXS)
Reported 2022-02-14 · Current development: unknownSource
Approved
NEXUS BIOPHARMA INC (NEXS)
Reported 2022-02-14 · Current development: unknownSource
Approved
FDA Decisions1 records
ApprovalINDICATIONS AND USAGE Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococ(NEXS)FDA ↗
ANDA215290UNKNOWNStandardOtherInjectable

Frequently asked questions

Which companies have sourced relationships with erythromycin lactobionate?

erythromycin lactobionate has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.

What is erythromycin lactobionate's latest FDA decision?

The most recent tracked FDA decision for erythromycin lactobionate is Approval for INDICATIONS AND USAGE Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococ, dated February 14, 2022.